Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines

Somatostatin analogs (SSA) are well-established antisecretory drugs in functionally active neuroendocrine tumors (NET). Two placebo-controlled trials have recently demonstrated significant improvement of progression-free survival under SSA treatment. Furthermore, somatostatin receptor (SSTR) overexp...

Descripción completa

Detalles Bibliográficos
Autores principales: Exner, Samantha, Prasad, Vikas, Wiedenmann, Bertram, Grötzinger, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897986/
https://www.ncbi.nlm.nih.gov/pubmed/29681888
http://dx.doi.org/10.3389/fendo.2018.00146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897986/
https://www.ncbi.nlm.nih.gov/pubmed/29681888
http://dx.doi.org/10.3389/fendo.2018.00146

Ejemplares similares